Go Pro
→ Whitney Tilson: “A New Kind of Civil War Begins in Less Than 100 Days” (From Stansberry Research) (Ad)tc pixel Free MENS Stock Alerts

Jyong Biotech (MENS) Competitors

Jyong Biotech logo
$2.06 -0.02 (-0.96%)
Closing price 04:00 PM Eastern
Extended Trading
$2.07 +0.01 (+0.49%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MENS vs. CRMD, AQST, DRUG, OCS, and TLRY

Should you buy Jyong Biotech stock or one of its competitors? Jyong Biotech's main competitors and comparable companies include CorMedix (CRMD), Aquestive Therapeutics (AQST), Bright Minds Biosciences (DRUG), Oculis (OCS), and Tilray Brands (TLRY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jyong Biotech compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

CorMedix has a net margin of 40.49% compared to Jyong Biotech's net margin of 0.00%. CorMedix's return on equity of 40.52% beat Jyong Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
CorMedix40.49% 40.52% 20.61%
Jyong Biotech N/A N/A N/A

34.2% of CorMedix shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Jyong Biotech had 1 more articles in the media than CorMedix. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for CorMedix. CorMedix's average media sentiment score of 0.94 beat Jyong Biotech's score of 0.00 indicating that CorMedix is being referred to more favorably in the media.

Company Overall Sentiment
CorMedix Positive
Jyong Biotech Neutral

CorMedix has higher revenue and earnings than Jyong Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CorMedix$457.20M1.32$163.05M$2.143.61
Jyong BiotechN/AN/A-$4.67MN/AN/A

CorMedix currently has a consensus target price of $15.00, suggesting a potential upside of 94.30%. Given CorMedix's stronger consensus rating and higher possible upside, equities research analysts clearly believe CorMedix is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CorMedix
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CorMedix has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

Summary

CorMedix beats Jyong Biotech on 11 of the 13 factors compared between the two stocks.

How does Jyong Biotech compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aquestive Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market.

Aquestive Therapeutics currently has a consensus price target of $9.17, indicating a potential upside of 98.84%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aquestive Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Jyong Biotech has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%.

Company Net Margins Return on Equity Return on Assets
Aquestive Therapeutics-144.63% N/A -52.40%
Jyong Biotech N/A N/A N/A

In the previous week, Aquestive Therapeutics had 11 more articles in the media than Jyong Biotech. MarketBeat recorded 12 mentions for Aquestive Therapeutics and 1 mentions for Jyong Biotech. Aquestive Therapeutics' average media sentiment score of 0.66 beat Jyong Biotech's score of 0.00 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aquestive Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jyong Biotech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Jyong Biotech has lower revenue, but higher earnings than Aquestive Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aquestive Therapeutics$44.54M12.99-$83.78M-$0.65N/A
Jyong BiotechN/AN/A-$4.67MN/AN/A

Summary

Aquestive Therapeutics beats Jyong Biotech on 9 of the 13 factors compared between the two stocks.

How does Jyong Biotech compare to Bright Minds Biosciences?

Jyong Biotech (NASDAQ:MENS) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jyong Biotech has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, suggesting that its stock price is 636% less volatile than the broader market.

Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 135.87%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Bright Minds Biosciences
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

In the previous week, Bright Minds Biosciences had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 1 mentions for Jyong Biotech. Bright Minds Biosciences' average media sentiment score of 0.02 beat Jyong Biotech's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jyong Biotech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bright Minds Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Jyong Biotech's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
Bright Minds Biosciences N/A -12.46%-12.30%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/A-$4.67MN/AN/A
Bright Minds BiosciencesN/AN/A-$8.74M-$2.08N/A

Summary

Bright Minds Biosciences beats Jyong Biotech on 7 of the 11 factors compared between the two stocks.

How does Jyong Biotech compare to Oculis?

Oculis (NASDAQ:OCS) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Jyong Biotech has lower revenue, but higher earnings than Oculis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oculis$1.45M405.46-$119.44M-$1.74N/A
Jyong BiotechN/AN/A-$4.67MN/AN/A

Oculis currently has a consensus target price of $39.44, indicating a potential upside of 289.00%. Given Oculis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Oculis is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Oculis has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

In the previous week, Oculis had 6 more articles in the media than Jyong Biotech. MarketBeat recorded 7 mentions for Oculis and 1 mentions for Jyong Biotech. Oculis' average media sentiment score of 0.53 beat Jyong Biotech's score of 0.00 indicating that Oculis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oculis
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Jyong Biotech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Jyong Biotech has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Jyong Biotech's return on equity of 0.00% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
Oculis-6,777.18% -42.61% -35.23%
Jyong Biotech N/A N/A N/A

22.3% of Oculis shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Oculis beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

How does Jyong Biotech compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Tilray Brands has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

Jyong Biotech has lower revenue, but higher earnings than Tilray Brands.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray Brands$915.45M0.59-$121.40M-$1.08N/A
Jyong BiotechN/AN/A-$4.67MN/AN/A

In the previous week, Tilray Brands had 16 more articles in the media than Jyong Biotech. MarketBeat recorded 17 mentions for Tilray Brands and 1 mentions for Jyong Biotech. Tilray Brands' average media sentiment score of 0.51 beat Jyong Biotech's score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tilray Brands
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Jyong Biotech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Jyong Biotech has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Jyong Biotech's return on equity of 0.00% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-13.11% -7.76% -5.59%
Jyong Biotech N/A N/A N/A

9.4% of Tilray Brands shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tilray Brands presently has a consensus target price of $8.00, suggesting a potential upside of 100.50%. Given Tilray Brands' stronger consensus rating and higher possible upside, research analysts plainly believe Tilray Brands is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.43
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Tilray Brands beats Jyong Biotech on 9 of the 14 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MENS vs. The Competition

Export
MetricJyong BiotechPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$156.62M$12.39B$7.18B$13.74B
Dividend YieldN/A2.64%2.57%12.64%
P/E RatioN/A797.25274.6625.48
Price / SalesN/A801.14683.57100.94
Price / CashN/A87.3377.0151.20
Price / Book-6.2410.4910.456.33
Net Income-$4.67M$2.81B$3.48B$358.24M
7 Day Performance3.52%2.83%0.88%1.20%
1 Month Performance1.98%3.30%0.03%-2.04%
1 Year Performance-96.02%3.58%18.28%5.41%

Jyong Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MENS
Jyong Biotech
N/A$2.06
-1.0%		N/A-96.1%$158.14MN/AN/A27
CRMD
CorMedix
2.9845 of 5 stars		$7.76
-1.7%		$15.00
+93.4%		-29.9%$604.46M$457.20M3.62191
AQST
Aquestive Therapeutics
2.5213 of 5 stars		$4.81
-1.5%		$9.17
+90.8%		-3.5%$603.08M$44.54MN/A147
DRUG
Bright Minds Biosciences
2.4153 of 5 stars		$60.48
-4.6%		$143.83
+137.8%		+37.8%$588.61MN/AN/A25
OCS
Oculis
2.2674 of 5 stars		$10.08
-5.0%		$38.00
+277.2%		-42.6%$584.15M$1.45MN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MENS) was last updated on 9/18/2026 by MarketBeat.com Staff.
From Our Partners
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
$747 million in one quarter - with a 60% cash-flow target
The company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...
Monument Traders Alliance | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Iran War WARNING: Something Just Changed
A powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...
Banyan Hill Publishing | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SPDR Gold just lost $14 billion.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel